
Caitlin Cox
News Editor at TCTMD
News Editor @TCTMD | Associate Director, Editorial Content @CRFheart | Knitter & Nerd | Winner of the 2020 @NIHCMfoundation Trade Journalism Award | She/Her
Articles
-
1 month ago |
tctmd.com | Caitlin Cox
The COVID pandemic could be a cause, but perhaps not the only reason, for the changes from 2018 to 2022. Only time will tell. One-year mortality rates—both cardiac and noncardiac—have been nudging upwards in recent years, according to an analysis of US data from 2017 to 2022. The COVID-19 pandemic could have driven the shift, researchers say, but it’s too early to know whether that trajectory will persist.
-
1 month ago |
tctmd.com | Caitlin Cox
Along with tafamidis and acoramidis, the drug is now the third for ATTR-CM, but it comes with a whopping price tag of $477,000 a year. Vutrisiran (Amvuttra), a small-interfering RNA (siRNA) therapy, is now the third drug approved by the US Food and Drug Administration for the treatment of adults with transthyretin amyloid cardiomyopathy (ATTR-CM), manufacturer Alnylam announced Thursday.
-
1 month ago |
tctmd.com | Caitlin Cox
In this “data-scarce zone,” the paper offers a road map for the first 24 hours and tips for transfer, teams, and more. In an effort to encourage best practices for cardiogenic shock care, the American College of Cardiology (ACC) has issued a consensus statement that provides practical advice to inform evaluation and management.
-
1 month ago |
tctmd.com | Caitlin Cox
The US data also point to lower costs and shorter stays at these expert centers, an argument for regionalized care akin to STEMI. Patients with cardiogenic shock have lower in-hospital mortality, as well as shorter, cheaper hospital stays, if transferred to expert hub centers, according to new US data. Yet just one in 10 people with cardiogenic shock were transferred, researchers report in their paper published earlier this month in Circulation: Heart Failure.
-
1 month ago |
tctmd.com | Caitlin Cox
Even modern cancer treatments appear risky for the heart, especially if the radiation dose to the LAD is high. Women with breast cancer who undergo contemporary radiation therapy see little change to left ventricular function in the first 5 years after treatment, according to observational data. At the same time, though, researchers picked up on “modest” worsening of diastolic function and measures of circumferential and longitudinal strain.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 4K
- DMs Open
- No

RT @pash22: Reinterventions Rare Yet Predictable After TAVI, French Registries study by @nicolasdumonte1 et al show https://t.co/BcoWkDCSmo…

RT @TCTMD_Yael: Introducing our Heart Sounds podcast with a new format! Have a listen — we look forward to talking again together next mont…

RT @GilbertTangMD: Thank you @TCTMD_Caitlin and @TCTMD for the interview and nice article on Redo #TAVR from the FRANCE2 registry publishe…